AB203. SOH25_AB_324. Systematic review of orally available selective estrogen receptor degraders (SERDS) in treatment of estrogen receptor positive (ER+) breast cancer
General Posters II

AB203. SOH25_AB_324. Systematic review of orally available selective estrogen receptor degraders (SERDS) in treatment of estrogen receptor positive (ER+) breast cancer

Thakksha Jeyakularajah1, Kelsi Gallati2, Amira Mahdi2

1Faculty of Education & Health Services, School of Medicine, University of Limerick, Garraun, Limerick, Ireland; 2Limerick Digital Cancer Research Centre, Health Research Institute, School of Medicine, University of Limerick, Limerick, Ireland

Background: Hormonal therapy (HT) plays a crucial role in the treatment of estrogen receptor positive (ER+) breast cancer by down-regulating estrogen signalling, it reduces the hormone-driven proliferation of cancerous cells. There are many forms of HT, such as aromatase inhibitors. Although these medications improve survival, resistance occurs in many patients due to a mutation in the ERα gene. However, selective estrogen receptor degraders (SERDs) work by targeting ERs for degradation, thereby overcoming this resistance mechanism. Previously, fulvestrant was the only approved SERD, a poor bioavailability compound that requires painful intramuscular injection. Currently, there are many novels orally available SERDs undergoing clinical trials with better bioavailability and a more convenient form of administration that may improve drug compliance and efficacy of treating ER+ breast cancer.

Methods: The purpose of this systematic review is to compare the findings from the clinical trials investigating oral SERDs to determine their efficacy, safety profile and pharmacokinetics. Systematic searches were done on multiple databases such as PubMed, Cochrane Library, and clinicaltrials.gov.

Results: Over 12 oral SERDs were identified in clinical development, and findings from various phases of trials were extracted. At present, only one oral SERD, Elacestrant, has been Food and Drug Administration (FDA) approved, while many others are in their phase III clinical trials.

Conclusions: This summary will provide an oversight of the developments in oral SERDs to determine how the treatment of ER+ breast cancer may progress in the future. However, with questions arising over prior therapy and treatment sequencing, further investigations are required to define a specific patient population for each SERD.

Keywords: Breast cancer; estrogen receptor (ER); selective estrogen receptor degrader (SERD); systematic review; hormonal therapy (HT)

AcknowledgmentsOther Section

None.

FootnoteOther Section

Funding: None.

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-25-ab203
Cite this abstract as: Jeyakularajah T, Gallati K, Mahdi A. AB203. SOH25_AB_324. Systematic review of orally available selective estrogen receptor degraders (SERDS) in treatment of estrogen receptor positive (ER+) breast cancer. Mesentery Peritoneum 2025;9:AB203.

Article Options

Download Citation

Share